Novel antipsoriatic fluidized spanlastic nanovesicles : In vitro physicochemical characterization, ex vivo cutaneous retention and exploratory clinical therapeutic efficacy
Copyright © 2019 Elsevier B.V. All rights reserved..
Tazarotene (TAZ) is a topical synthetic retinoid used in psoriasis treatment, however, it is extremely lipophilic and exhibits skin irritation. Research is in a state of continuous advancement in the field of nanocarriers fabrication, and in this regard, we investigated the formulation of novel topically oriented nanovesicles; representing a combination of spanlastics and penetration enhancer vesicles, to be termed (fluidized-SNs). TAZ-loaded fluidized SNs were physicochemically characterized, tested for ex vivo cutaneous retention, and the selected formulation was compared with the marketed product Acnitaz® regarding clinical antipsoriatic activity. The selected fluidized-SNs enriched with 1% cineole exhibited high entrapment for TAZ (76.19%), suitable size and zeta potential of 241.5 ± 5.68 nm and -36.10 ± 2.50 mV respectively, and retaining of stability after refrigeration storage for one month. As hypothesized, cineole enriched fluidized-SNs exhibited remarkable TAZ deposition amounting to a total of 81.51% in the different skin layers. Upon clinical assessment, the presented formulation displayed superior traits compared to the marketed product, in terms of dermoscopic imaging, morphometric analysis of psoriatic lesions, and statistical analysis of PASI scores. Results confirmed that the prepared novel fluidized spanlastics formulation holds great promise for the treatment of psoriasis, and its benefit should futuristically be investigated in other topical diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:568 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 568(2019) vom: 10. Sept., Seite 118556 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Elmowafy, Enas [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.01.2020 Date Revised 23.01.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijpharm.2019.118556 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299607070 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299607070 | ||
| 003 | DE-627 | ||
| 005 | 20231225100712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2019.118556 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0998.xml |
| 035 | |a (DE-627)NLM299607070 | ||
| 035 | |a (NLM)31348982 | ||
| 035 | |a (PII)S0378-5173(19)30600-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Elmowafy, Enas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel antipsoriatic fluidized spanlastic nanovesicles |b In vitro physicochemical characterization, ex vivo cutaneous retention and exploratory clinical therapeutic efficacy |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.01.2020 | ||
| 500 | |a Date Revised 23.01.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier B.V. All rights reserved. | ||
| 520 | |a Tazarotene (TAZ) is a topical synthetic retinoid used in psoriasis treatment, however, it is extremely lipophilic and exhibits skin irritation. Research is in a state of continuous advancement in the field of nanocarriers fabrication, and in this regard, we investigated the formulation of novel topically oriented nanovesicles; representing a combination of spanlastics and penetration enhancer vesicles, to be termed (fluidized-SNs). TAZ-loaded fluidized SNs were physicochemically characterized, tested for ex vivo cutaneous retention, and the selected formulation was compared with the marketed product Acnitaz® regarding clinical antipsoriatic activity. The selected fluidized-SNs enriched with 1% cineole exhibited high entrapment for TAZ (76.19%), suitable size and zeta potential of 241.5 ± 5.68 nm and -36.10 ± 2.50 mV respectively, and retaining of stability after refrigeration storage for one month. As hypothesized, cineole enriched fluidized-SNs exhibited remarkable TAZ deposition amounting to a total of 81.51% in the different skin layers. Upon clinical assessment, the presented formulation displayed superior traits compared to the marketed product, in terms of dermoscopic imaging, morphometric analysis of psoriatic lesions, and statistical analysis of PASI scores. Results confirmed that the prepared novel fluidized spanlastics formulation holds great promise for the treatment of psoriasis, and its benefit should futuristically be investigated in other topical diseases | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical efficacy | |
| 650 | 4 | |a Cutaneous retention | |
| 650 | 4 | |a Psoriasis | |
| 650 | 4 | |a Spanlastic nanovesicles | |
| 650 | 4 | |a Tazarotene | |
| 650 | 7 | |a Dermatologic Agents |2 NLM | |
| 650 | 7 | |a Hexoses |2 NLM | |
| 650 | 7 | |a Nicotinic Acids |2 NLM | |
| 650 | 7 | |a Polysorbates |2 NLM | |
| 650 | 7 | |a tazarotene |2 NLM | |
| 650 | 7 | |a 81BDR9Y8PS |2 NLM | |
| 650 | 7 | |a sorbitan monostearate |2 NLM | |
| 650 | 7 | |a NVZ4I0H58X |2 NLM | |
| 650 | 7 | |a Eucalyptol |2 NLM | |
| 650 | 7 | |a RV6J6604TK |2 NLM | |
| 700 | 1 | |a El-Gogary, Riham I |e verfasserin |4 aut | |
| 700 | 1 | |a Ragai, Maha H |e verfasserin |4 aut | |
| 700 | 1 | |a Nasr, Maha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d 1992 |g 568(2019) vom: 10. Sept., Seite 118556 |w (DE-627)NLM07779785X |x 1873-3476 |7 nnns |
| 773 | 1 | 8 | |g volume:568 |g year:2019 |g day:10 |g month:09 |g pages:118556 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpharm.2019.118556 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 568 |j 2019 |b 10 |c 09 |h 118556 | ||